Ioannis Farmakis
Overview
Explore the profile of Ioannis Farmakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar S, Yoon S, Milioglou I, Tashtish N, Farmakis I, Dallan L, et al.
Am J Cardiol
. 2023 Jul;
202:176-181.
PMID: 37441832
Atrial fibrillation is the most common arrhythmia in patients with underlying malignancy. Patients with cancer have a higher risk of bleeding, and at the same time, carry an elevated risk...
2.
Milioglou I, Farmakis I, Wazirali M, Ajluni S, Khawaja T, Chatuverdi A, et al.
J Thromb Thrombolysis
. 2022 Dec;
55(2):228-242.
PMID: 36536090
Catheter-directed interventions have slowly been gaining ground in the treatment of pulmonary embolism (PE), especially in patients with increased risk of bleeding. The goal of this study is to summarize...
3.
Antza C, Farmakis I, Doundoulakis I, Akrivos E, Stalikas N, Zafeiropoulos S, et al.
J Hypertens
. 2022 Jun;
40(6):1053-1059.
PMID: 35703872
Blood pressure (BP) phenotypes have a prognostic significance for target organ damage in long-term studies. However, it remains uncertain whether a single baseline phenotype classification is reproducible over time and...
4.
Farmakis I, Kosmidis D, Liantzakis C, Serasli E, Karvounis H, Koutsakis A, et al.
Int J Cardiol Congenit Heart Dis
. 2022 Apr;
3:100097.
PMID: 35359462
No abstract available.
5.
Psarakis G, Farmakis I, Zafeiropoulos S, Kourti O, Konstantas O, Vrana E, et al.
Angiology
. 2021 Nov;
73(5):453-460.
PMID: 34779272
Our study aimed to investigate the association between platelet indices and their in-hospital change and long-term prognosis in acute coronary syndrome (ACS). Data from a randomized controlled trial (NCT02927808) recruiting...
6.
Goulas I, Farmakis I, Doundoulakis I, Antza C, Kollios K, Economou M, et al.
J Hypertens
. 2021 Sep;
40(2):197-204.
PMID: 34475347
Background And Objectives: In 2017, the American Academy of Pediatrics (AAP) recommended new blood pressure (BP) thresholds for the diagnosis of hypertension in children and adolescents. We assessed the impact...
7.
Doundoulakis I, Gavriilaki M, Tsiachris D, Arsenos P, Antoniou C, Dimou S, et al.
Cardiovasc Drugs Ther
. 2021 Jun;
36(5):951-958.
PMID: 34089429
Purpose: Atrial high-rate episodes (AHREs) recorded with cardiac implantable electronic devices (CIEDs) have been associated with the development of clinical atrial fibrillation (AF) and increase in stroke and death risk....
8.
Milioglou I, Farmakis I, Neudeker M, Hussain Z, Guha A, Giannakoulas G, et al.
J Thromb Thrombolysis
. 2021 May;
52(4):1137-1150.
PMID: 34024021
Background: Four-factor prothrombin complex concentrate (PCC) is frequently used as a reversal agent for major bleeding in patients on factor Xa inhibitors. Piran et al. reviewed its safety and efficacy...
9.
Zafeiropoulos S, Farmakis I, Kartas A, Arvanitaki A, Pagiantza A, Boulmpou A, et al.
Atherosclerosis
. 2021 Mar;
323:37-43.
PMID: 33780749
Background And Aims: Achieving the low-density lipoprotein cholesterol (LDL-C) goal following an acute coronary syndrome (ACS) is a milestone often missed due to suboptimal adherence to secondary prevention treatments. Whether...
10.
Zafeiropoulos S, Pagiantza A, Doundoulakis I, Stalikas N, Farmakis I, Samaras A, et al.
Curr Pharm Des
. 2021 Jan;
27(8):1068-1079.
PMID: 33463455
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a new antihyperglycemic class with the demonstrated advantage of reducing major adverse cardiovascular events (MACE) among individuals with type 2 diabetes...